National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London,London,UK.
Trimbos Institute, Netherlands Institute of Mental Health and Addiction,Utrecht,the Netherlands.
Psychol Med. 2018 Oct;48(14):2346-2352. doi: 10.1017/S0033291717003877. Epub 2018 Jan 31.
The number of people entering specialist drug treatment for cannabis problems has increased considerably in recent years. The reasons for this are unclear, but rising cannabis potency could be a contributing factor.
Cannabis potency data were obtained from an ongoing monitoring programme in the Netherlands. We analysed concentrations of δ-9-tetrahydrocannabinol (THC) from the most popular variety of domestic herbal cannabis sold in each retail outlet (2000-2015). Mixed effects linear regression models examined time-dependent associations between THC and first-time cannabis admissions to specialist drug treatment. Candidate time lags were 0-10 years, based on normative European drug treatment data.
THC increased from a mean (95% CI) of 8.62 (7.97-9.27) to 20.38 (19.09-21.67) from 2000 to 2004 and then decreased to 15.31 (14.24-16.38) in 2015. First-time cannabis admissions (per 100 000 inhabitants) rose from 7.08 to 26.36 from 2000 to 2010, and then decreased to 19.82 in 2015. THC was positively associated with treatment entry at lags of 0-9 years, with the strongest association at 5 years, b = 0.370 (0.317-0.424), p < 0.0001. After adjusting for age, sex and non-cannabis drug treatment admissions, these positive associations were attenuated but remained statistically significant at lags of 5-7 years and were again strongest at 5 years, b = 0.082 (0.052-0.111), p < 0.0001.
In this 16-year observational study, we found positive time-dependent associations between changes in cannabis potency and first-time cannabis admissions to drug treatment. These associations are biologically plausible, but their strength after adjustment suggests that other factors are also important.
近年来,寻求专业药物治疗大麻问题的人数显著增加。原因尚不清楚,但大麻效力的上升可能是一个促成因素。
大麻效力数据来自荷兰正在进行的监测计划。我们分析了每个零售店出售的最受欢迎的国产草药大麻品种的 δ-9-四氢大麻酚(THC)浓度(2000-2015 年)。混合效应线性回归模型研究了 THC 与首次大麻进入专业药物治疗之间的时间依赖性关联。根据欧洲规范药物治疗数据,候选时间滞后为 0-10 年。
从 2000 年到 2004 年,THC 从平均(95%CI)8.62(7.97-9.27)增加到 20.38(19.09-21.67),然后在 2015 年降至 15.31(14.24-16.38)。首次大麻就诊(每 10 万居民)从 2000 年到 2010 年从 7.08 上升到 26.36,然后在 2015 年降至 19.82。在 0-9 年的滞后时间内,THC 与治疗进入呈正相关,最强的关联在 5 年时,b = 0.370(0.317-0.424),p <0.0001。在调整年龄、性别和非大麻药物治疗就诊后,这些正相关在 5-7 年的滞后时间内减弱,但仍具有统计学意义,在 5 年时再次最强,b = 0.082(0.052-0.111),p <0.0001。
在这项为期 16 年的观察研究中,我们发现大麻效力的变化与首次大麻进入药物治疗之间存在正相关的时间依赖性关联。这些关联在生物学上是合理的,但在调整后它们的强度表明其他因素也很重要。